Health And Pharma
Health & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report directly from the news sources and strive to be recognized as a trusted news platform.
Posts | Health And Medicine
Dec 21, 2024 · Health & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report directly from the news sources and strive to be recognized as a trusted news platform.
About Us - Health And Pharma
Health & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report directly from the news sources and strive to be recognized as a trusted news platform.
ONCOLife | Health And Medicine
About ONCOLife. ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is dedicated to covering key developments in the field of oncology.
AI-Powered Treatment Success: LP-300 Shows Promise for Non …
Aug 12, 2024 · The Phase 2 HARMONIC™ trial, leveraging the AI-assisted RADR® platform, demonstrates promising outcomes for LP-300 in treating non-smoker lung cancer patients, with an 86% clinical benefit rate.
Posts | Health And Medicine
Nimbus Reports Early Success in Treating Solid Tumors with NDI-101150, an HPK1 Inhibitor. Clinical Trials | 24 May 2024
How AI is Shaping Drug Discovery: LP-300 in Lung Cancer Treatment
Nov 27, 2024 · Could you explain how LP-300's mechanism of action interacts with tyrosine kinase inhibitors and affects cancer cells in never smokers? Dr. Reggie Ewesuedo: LP-300 has been under development for some time, initially with a recognized mechanism of action unrelated to its effects on tyrosine kinase receptors.It’s known to resensitize tumor cells to chemotherapeutic agents by resetting the ...
Posts | Health And Medicine
The OVATION 2 Study and the Novel Immunotherapy IMNN-001 for Ovarian Cancer. ONCOLife | 12 September 2024
FDA Approves Ziihera as First Dual HER2-Targeted Therapy for …
Nov 22, 2024 · Clinical Trial Insights. The HERIZON-BTC-01 trial assessed the efficacy of Ziihera in 62 patients with HER2-positive BTC, achieving a confirmed objective response rate of 52%. The trial not only met its primary endpoints but also provided hope for improved survival outcomes, with a median duration of response nearing 15 months.
First-Ever Obstructive Sleep Apnea Drug, Zepbound, Approved by …
Dec 21, 2024 · Reduced Breathing Interruptions: Participants not on PAP therapy reduced their breathing interruptions (apnea or shallow breathing) by 25 events per hour on average with Zepbound, compared to just 5 events per hour with a placebo.In those on PAP therapy, the reduction was 29 events per hour for Zepbound vs 6 per hour for placebo. Alleviation of OSA Symptoms: Nearly half of participants ...